JERUSALEM, February 14, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, was contacted by McKesson Corporation, a major distributor of health care systems, medical supplies, and pharmaceutical products, for potential cooperation once customer feedback of its device has been received from early pilots in US hospitals.
As an early adopter of new technologies, McKesson approached Medisafe 1 Technologies to explore the potential of Medisafe 1 Technologies' patented syringe locking device. McKesson is particularly interested to learn how the device will work with Barcoded Point of Care (BPOC) systems in hospitals. The aim is to reduce the number of injuries and deaths related to improper administration of medications.
"Since McKesson is a leader in implementing necessary safety measures across the American health system, our syringe locking device would be a valuable addition to its products and solutions," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "We are progressing with a pilot in a clinical setting to meet McKesson's requirements for cooperation."
Once positive customer feedback from the pilot(s) has been received, further commercial discussions may commence.
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes, and improving the quality and safety of patient care. Over the course of its 178-year history, McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payers; hospital and retail pharmacy automation; and services for manufacturers and payers designed to improve outcomes for manufacturers and payers designed to improve outcomes for patients.
For more information, visit http://www.mckesson.com
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
For more information, visit http://www.medisafe1.com
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov
Media Contact: Jacob Elhadad CEO +972-524440000 Jacob.firstname.lastname@example.org